Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection
Retrieved on:
Tuesday, August 8, 2023
Health, FDA, Radiology, Research, Science, Pharmaceutical, Biotechnology, GFR, Pregnancy, Central nervous system, Gadobutrol, Fresenius (company), Diabetes, NSF, CAD, History, Glomerular filtration rate, Brain, USP, Hypertension, Contraindication, Incidence, Acute kidney injury, MRI, Hospital, Magnetic resonance imaging, Dizziness, Patient, Risk, Nephrogenic systemic fibrosis, Nausea, Coronary artery disease, Headache, Anaphylaxis, Rest, Death, Gadolinium, Medical imaging, Pharmaceutical industry, Birth control, Vaccine
Fresenius Kabi Gadobutrol Injection, a high-relaxivity macrocyclic agent, is available immediately in the United States.
Key Points:
- Fresenius Kabi Gadobutrol Injection, a high-relaxivity macrocyclic agent, is available immediately in the United States.
- It is the second MRI offering in the company’s growing radiology portfolio , which also includes:
"Fresenius Kabi is pleased to introduce Gadobutrol Injection as the newest addition to our U.S. radiology portfolio, expanding the range of cost-effective contrast agent options available to hospitals and clinics," said John Ducker, president and CEO of Fresenius Kabi USA. - Gadobutrol Injection is a gadolinium-based contrast agent indicated for use with MRI.1 It is the fourth product offering in the Fresenius Kabi radiology portfolio, which first launched in July 2022 with the introduction of Iodixanol Injection, USP during a nationwide shortage.
- Fresenius Kabi Gadobutrol Injection is preservative-free, and the container closure is not made with natural rubber latex.